These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 24536073)

  • 1. New strategies for triple-negative breast cancer--deciphering the heterogeneity.
    Mayer IA; Abramson VG; Lehmann BD; Pietenpol JA
    Clin Cancer Res; 2014 Feb; 20(4):782-90. PubMed ID: 24536073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subtyping of triple-negative breast cancer: implications for therapy.
    Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
    Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of molecular heterogeneity in triple negative breast cancer.
    Lehmann BD; Pietenpol JA
    Breast; 2015 Nov; 24 Suppl 2(0 2):S36-40. PubMed ID: 26253813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
    Lehmann BD; Jovanović B; Chen X; Estrada MV; Johnson KN; Shyr Y; Moses HL; Sanders ME; Pietenpol JA
    PLoS One; 2016; 11(6):e0157368. PubMed ID: 27310713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple-negative breast cancer molecular subtyping and treatment progress.
    Yin L; Duan JJ; Bian XW; Yu SC
    Breast Cancer Res; 2020 Jun; 22(1):61. PubMed ID: 32517735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular Heterogeneity of Triple Negative Breast Cancer.
    Abramson VG; Mayer IA
    Curr Breast Cancer Rep; 2014 Sep; 6(3):154-158. PubMed ID: 25419441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biology and Management of Patients With Triple-Negative Breast Cancer.
    Sharma P
    Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The treatment landscape of triple-negative breast cancer.
    Hu Y; Wang C; Liang H; Li J; Yang Q
    Med Oncol; 2024 Aug; 41(10):236. PubMed ID: 39210220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
    Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
    Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tackling intra- and inter-tumor heterogeneity to combat triple negative breast cancer.
    Wright N; Rida PCG; Aneja R
    Front Biosci (Landmark Ed); 2017 Jun; 22(9):1549-1580. PubMed ID: 28410132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
    Sharma P
    Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
    Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
    Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triple-negative breast cancer: advancements in characterization and treatment approach.
    Hurvitz S; Mead M
    Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Bai X; Ni J; Beretov J; Graham P; Li Y
    Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
    Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
    Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic landscape in mutational triple negative breast cancer.
    Shi Y; Jin J; Ji W; Guan X
    Mol Cancer; 2018 Jul; 17(1):99. PubMed ID: 30007403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triple Negative Breast Cancer: A Tale of Two Decades.
    Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM
    Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.
    Mai N; Abuhadra N; Jhaveri K
    Clin Breast Cancer; 2023 Dec; 23(8):784-799. PubMed ID: 37336650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.